Author's reply.

To the Editor,

I would like to thank the authors for their supportive comments and valuable contributions to our article entitled “A novel oral anticoagulant, dabigatran, in acute renal infarction” published in the February 2015 issue of the Anatolian Journal of Cardiology (1).

Unfortunately, there are no clinical research data or therapeutic guidelines for acute renal infarction (ARI). Instead of invasive procedures, conservative therapy (hydration or systemic anticoagulation) is favorable in unilateral ARI (2). We preferred dabigatran as the oral anticoagulant in the conservative therapy of ARI and obtained an excellent clinical outcome. It is also possible that dabigatran had some potential renoprotective effects, which provide the excellent clinical outcome in our case in accordance with that in an experimental study by Yazıcı et al. (3) However, our article is only a case report; therefore, further comprehensive cohort studies are required to prove the possible renoprotective effects (organ specific and cellular) of dabigatran.